Sodium –Glucose Cotransporter-2 Inhibitors for Heart Failure: The New Kid on the Block

Sodium –glucose cotransporter-2 (SGLT2) inhibitors recently emerged as an effective therapy for heart failure (HF) with reduced ejection fraction. Recent published clinical trials have confirmed these agents substantially reduce mortality and HF hospitalization among patients with established HF with red uced ejection fraction, with or without type 2 diabetes. Ongoing studies are evaluating the effects of SGLT2 inhibitors on clinical outcomes for patients with HF with preserved ejection fraction. Nurse practitioners must understand the indications and mechanisms of SGLT2 inhibitors when prescribing.

Source: The Journal for Nurse Practitioners - March 5, 2021 Category: Nursing Authors: Jaime McDermott, Carolina Tennyson, Elizabeth Bell-McClure Tags: Original Research Source Type: research